Latest Commercialisation News

Sparc Technologies has successfully raised up to A$2.7 million through a share placement and a Share Purchase Plan, positioning the company to accelerate commercialisation of its graphene additive ecosparc and support its green hydrogen pilot projects.

ClearVue Technologies has secured its first commercial rooftop contract in Sydney’s CBD, supplying innovative solar glass for the City Tattersalls Club redevelopment to boost sustainability and energy efficiency.

Nanoveu Limited has successfully raised $2.3 million through a share placement to accelerate development and commercialization of its cutting-edge semiconductor, 3D visualization, and solar coating technologies.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Assetora Limited has dramatically reduced its net liabilities and strengthened its balance sheet through strategic capital raises and debt conversions, while unveiling a comprehensive rebrand and leadership expansion to drive its next growth phase.

Australian Strategic Materials (ASM) outlines progress on its Korean Metals Plant ramp-up, strategic plans for a US metals facility, and conditional funding support for the Dubbo Project, reinforcing its mine-to-metals supply chain ambitions.

Horseshoe Metals Limited has reignited development at its Horseshoe Lights Copper-Gold Project, securing a $4 million convertible loan and entering a strategic agreement with Melody Gold to process gold surface materials, positioning the company for early cash flow and expanded exploration.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.

PARKD Limited has secured a pivotal 5-year exclusive licence with Fielders for its metal deck support IP, completed a major car storage facility, and reported positive operating cash flow in Q3 FY25, positioning the company for expanded commercial growth.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

Environmental Clean Technologies Limited has commissioned batch-scale granulation equipment and produced its first 12 tonnes of COLDry Fertiliser, while securing $1.75 million in capital through placements and convertible notes to support ongoing project financing.

Nanoveu Limited has completed its strategic acquisition of EMASS, advancing its foothold in ultra-low-power AI-driven edge computing. The company also strengthened its leadership team and secured additional capital to fuel growth.